It’s been a busy week for Alzheimer’s news, which is what usually happens when the Alzheimer’s Association sponsors a big conference like one in Toronto at which various researchers have been presenting findings.

An Aging Edge report on Monday explained the intriguing result of a study that involved use of a computerized speed processing game. A group of healthy older adults using that kind of training in a broad national study developed dementia at a significantly lower rate than other groups monitored over 10 years. It was the first finding of its kind, and analysts said further study of this potential cognitive training benefit was in order.

And now a positive stir has come from a drug known as LMTM, from TauRx Therapeutics Ltd., which is aimed at combating tau tangles in the brain, unlike most past anti-Alzheimer’s pharmaceutical research aimed at getting rid of amyloid plaque. In Phase 3 of a trial, people with mild to moderate Alzheimer’s who took LMTM maintained their cognitive functioning better. It only worked for those taking it alone instead of in combination with other Alzheimer’s medications. CNN described the LMTM findings with notes of both caution and hope — “Testing of new Alzheimer’s drug disappoints, but it’s not all bad news” — which is better than most of the news in recent years with such research.

There has been ongoing debate over whether tau or amyloid has more to do with causing or being a sign of Alzheimer’s and which one needs to be the focus of drug testing. Researchers have been throwing things against the wall for years to see what sticks and repeatedly have been frustrated by different therapies. Alzheimer’s Association chief science officer Maria Carrillo said LMTM could be a significant step forward, though additional research is needed with a broader population of participants.

Advertise with us

“In Alzheimer’s, the most likely scenario for successful future treatment is addressing the disease from multiple angles,” she said in a press release. “The results of this Phase 3 trial are interesting but also complex, and it will take time for the field to determine what they mean.”

Other interesting research outlined at the conference suggested that people whose work involves both complex thinking and interacting with other people — as opposed to working with data or physical things — achieve better protection against Alzheimer’s disease than do other people. It has previously been noted that people who are more educated seem to have a better brain reserve that delays the disease in many instances.

In two more studies presented, a decline in odor identification abilities was cited as a possible early predictor of cognitive decline. It’s hard to detect and diagnose Alzheimer’s, especially in its early stages, and the researchers said sense of smell appears to be one low-cost marker meriting more exploration.

The Associated Press reported on research into “mild behavioral impairment,” in which problematic personality changes can show up as an early sign of dementia instead of it necessarily being evident only from the more common memory problems associated with Alzheimer’s.

Whenever hundreds of Alzheimer’s researchers and experts get together, new suggestions abound of what can help identify the disease earlier or postpone symptoms or make it less likely to occur. What has yet to occur is agreement on anything resembling a cure. The federal government’s Alzheimer’s national plan has made that a goal to achieve within the next decade.

Gary Rotstein: grotstein@post-gazette.com or 412-263-1255.